Combinations for Treating EGFR Acquired Resistance

download report

Transcript Combinations for Treating EGFR Acquired Resistance

Combinations for Treating EGFR
Acquired Resistance
Melissa L. Johnson, MD
Acquired Resistance Patient Forum
In ALK, ROS1 & EGFR Lung Cancers
September 6, 2014 | Boston
Combination Treatments for EGFR Acquired Resistance
Dx: EGFR+ lung
cancer
Tarceva
Gilotrif
Acquired
Resistance
Tarceva
+
NEW DRUG
Gilotrif
+
NEW DRUG
Combination Treatments for EGFR Acquired Resistance
Can we make 1st Gen TKI Better?
• We have tried!!
• Selected approaches to enhancing EGFR TKI in order to overcome or
prevent resistance
Erlotinib + Chloroquine
Erlotinib + Sirolimus
Erlotinib + Onartuzumab (anti-Met)
Erlotiinb + Entinostat
Erlotinib + R1507 (anti IGF-1)
Erlotinib + Tivantinib
Erlotinib + Sorafanib
Erlotinib + Dasatinib
Erlotinib + MK2206 (AKT)
Erlotinib + MM-121 (anti-ErbB3)
Erlotinib + XL184
Erlotinib + Rilotumumab (anti-HGF)
Erlotinib + Patritumumab (anti-ErbB3)
Erlotinib + AUY-922 (HSP 90 inhibitor)
Slide adapted, courtesy of Thomas J. Lynch, Jr., MD
Combination Treatments for EGFR Acquired Resistance
Dx: EGFR+ lung
cancer
Tarceva/Gilotrif
(erlotinib/afatinib)
+
NEW DRUG
Acquired
Resistance
Combination Treatments for EGFR Acquired Resistance
Flare associated with shorter TTP
14 of 61 patients (23%, 95% CI 14-35%) had a disease flare
(hospitalization or death)
• Median time from last TKI to flare was 8 days (range 3-21 days)
• 3 patients went on to trial treatment
•
Chaft, Clin Cancer Res 2011
Combination Treatments for EGFR Acquired Resistance
AUY922:
An “Onco-Chaperone” Inhibitor
AUY922 (in yellow) is a synthetic isoxazole resorcinol HSP90
inhibitor, shown here bound to the deep ATP pocket of
HSP90 (in blue)
Neckers and Workman Clin Cancer Res 2012
AUY922+ Erlotinib
Melissa L. Johnson
Combination Treatments for EGFR Acquired Resistance
AUY922 + Erlotinib
Phase I Dose-Escalation
Cohort
Dose of AUY922 IV
weekly
Dose of Erlotinib PO
daily
# pts enrolled
1
2
3
4
5
25 mg/m2
25 mg/m2
37.5 mg/m2
55 mg/m2
70 mg/m2
75 mg
150 mg
150 mg
150 mg
150 mg
3
3
3
3
6
AUY922+ Erlotinib
Melissa L. Johnson
HSP90 Inhibitors in Lung Adenocarcinoma
Preliminary Activity
Patient 01-102
AUY922 25 mg/m + Erlotinib 75 mg
Duration of therapy: 6 months
C1D1
AUY922+ Erlotinib
C1D28
Melissa L. Johnson
AUY922 + Erlotinib
Phase II Study Design
Stage IV
Adenocarcinoma
+EGFR mutation
Acquired Resistance
Biopsy at resistance
30 day erlotinib lead-in
Erlotinib 150mg PO qday
AUY922 70mg/m2
Key Inclusion Criteria
•Advanced lung adenocarcinoma
•EGFR mutation OR previous response to EGFR TKI
•EGFR TKI for ≥6 months and 1 full month prior to
study start
•Biopsy at time of acquired resistance to EGFR TKI
Key Exclusion Criteria
•Brain metastasis that are symptomatic and/or
requiring escalating doses of steroids
•Systemic treatment within 4 weeks, RT within 2
weeks
Primary endpoint: Overall response rate ORR (CR + PR)
Secondary endpoints: Progression-free survival, Overall survival, ORR in T790M+, Toxicity
Definition of Acquired Resistance19
• Previously treated with single-agent EGFR-TKI
• Tumor harbors TKI-sensitive EGFR mutation (G719X, ex 19 del, L858R,
L861Q)
• EITHER RECIST-defined PR/CR OR ≥ 6 months clinical benefit (SD) with
single-agent EGFR-TKI followed by systemic POD
19
Jackman JCO 2009
Statistical Considerations:
• stage I: 16 pts (if ≥2 responses, proceed to stage II)
• stage II: 9 pts (if ≥ 5 responses overall, AUY922 and erlotinib
are worthy of further study)
• α=10%; β=10%; p0=10%; p1=30%
Melissa L. Johnson
Molecular Characteristics
N=37
AUY922
25-55
2
mg/m
N=12
AUY922
70
2
mg/m
N=25
EGFR exon 19 deletion
25
10
15
EGFR exon 21 L858R
11
2
9
EGFR exon 21 L861Q:
1
0
1
EGFR T790M found on repeat Tumor Biopsy, n (%)
16 (43%)
6 (50%)
10 (40%)
Median duration of EGFR-TKI therapy prior to
developing acquired resistance, months (range)
12 (2-42) 13 (8-32) 11(2-42)
Primary EGFR mutations
EGFR mutation unknown
AUY922+ Erlotinib
Melissa L. Johnson
Best Response to AUY922 and Erlotinib
100%
N=24
Best % change in target lesions
80%
60%
40%
20%
0%
-20%
-40%
Progressive disease
Stable disease
Partial response
EGFR T790M
-60%
Partial Response (PR): 4/25 (16%)(95% CI 6-35%)
Disease Control Rate (DCR): 14/25 (56%)(95% CI 37-73%)
AUY922+ Erlotinib
Melissa L. Johnson
Individual Responses According to EGFR Mutations and Time on Primary EGFR-TKI
Pt ID
96-501
96-502
96-503
96-504
01-505
96-506
96-02
96-03
96-04
96-05
96-06
96-07
96-08
96-09
96-10
96-11
96-12_
96-13
96-14
96-15
96-16
96-17
96-18
96-19
01-20_
EGFR
19/21
21
21
19
21
L861Q
21
19
19
19
19
21
21
21
19
21
19
21
19
19
19
19
21
19
19
19
*
T790M
Best
Response
AUY922 +
Erlotinib
Cycles
Completed
Duration
primary
EGFR-TKI
(prior to AR)
T790M
T790M*
T790M
—
—
T790M
—
—
T790M
—
—
—
T790M
Unk
—
T790M
—
T790M
—
—
—
T790M
—
—
T790M
SD
SD
PR
POD
POD
POD
POD
POD
POD
SD
SD
POD
POD
POD
POD
PR
PR
PR
SD
NEΩ
SD
SD
POD
NE∆
NE∆
2
1
2
1
1
1
1
1
1
3
3
1
1
1
1
3
13
3
1
1
2
6
1
1
2
7.43
11.00
11.57
9.57
10.00
20.80
25.63
4.40
10.10
2.30
17.87
11.93
12.80
8.83
15.47
42.00
19.80
25.00
14.77
7.50
6.60
10.73
3.03
16.63
6.00
Small cell transformation
Reason withdrawn from study
DLT-prolonged QTc; junctional rhythm
Ophthalmologic tox ( gr 2 night blindness)
Ophthalmologic tox (gr 2 night blindness/blurred)
POD
POD
POD
POD
POD
POD
POD
Patient withdrew consent
POD
POD
Patient withdrew consent
POD
Patient withdrew consent
Hepatic tox (gr 3 LFT elevation)
Opthalmologic tox (gr 2 night blindness)
Hepatic tox (gr 3 LFT elevation)
Diarrhea (gr 3 colitis)
POD
POD
POD
POD
patient remains on study
Combination Treatments for EGFR Acquired Resistance
Afatinib + Cetuximab
Combination Treatments for EGFR Acquired Resistance
Dual Inhibition of EGFR with Afatinib and Cetuximab
in Kinase Inhibitor-Resistant EGFR Mutant Lung
Cancer with and without T790M
Dose escalation schema 3–6
patients per cohort
Pathology confirmed
NSCLC with
EGFR
mutation1
OR
SD 6 months
on erlotinib/gefitinib
OR
Partial or complete
response
to erlotinib/gefitinib
ECOG PS 0-2
Age ≥ 18 years
Disease
progression2
Stop erlotinib/
gefitinib for
≥72 hours3
Afatinib p.o. daily + escalating
doses of i.v. cetuximab q 2
weeks
Dose levels starting at:
afatinib 40 mg +
cetuximab 250 mg/m2
Predefined maximum dose:
afatinib 40 mg +
cetuximab 500 mg/m2
MTD cohort expanded up to 80 EGFR
mutation-positive patients4:
40 T790M+ and 40 T790M–
Janjigian, et al. Cancer Discovery 4(9): 1-10, 2014
Combination Treatments for EGFR Acquired Resistance
Tumor Regression by T790M Mutation Status
at Recommended Dose
Horn at al. IASLC 2011
16
Janjigian, et al. Cancer Discovery 4(9): 1-10, 2014
Combination Treatments for EGFR Acquired Resistance
Cetux/Afatanib Toxicity
N=126
All grades
Gr 3-4
Rash
114 (90%)
25 (20%)
Diarrhea
89 (71%)
8 (6%)
Nail Effect
72 (57%)
0 (0%)
Stomatitis
71 (56%)
1 (1%)
Fatigue
59 (47%)
3 (2%)
Nausea
53 (42%)
3 (2%)
Xerosis
53 (42%)
3 (2%)
Janjigian, et al. Cancer Discovery 4(9): 1-10, 2014
Combination Treatments for EGFR Acquired Resistance
Preliminary Efficacy Comparison
RR
T790M +
RR
T790M -
PFS
(months)
Tarceva/AUY922
30%
10%
1.7
Afatanib/Cetux
32%
28%
4.66
CO-1686
58%
Inc.

AZD 9291
65%
22%

18
Toxicity Comparison
Diarrhea
Rash
Unique Toxicities
Tarceva/AUY922
95%
81%
Afatanib/Cetux
71%
97%
Night blindness, elevated LFTs,
prolongation of QTc
Nail effects, stomatitis
Tarceva/Bevacizu
mab
81%
99%
Any Grade
19
Hypertension, Proteinuria
Combination Treatments for EGFR Acquired Resistance
T+A vs T (#8005)
• BeTa in second line setting
• ATLAS as maintenance
Unselected
Patient
Population
– Both with compelling results in enriched
populations of never smokers, East Asians
• Possible EGFR regulation of VEGF in EGFR
mutant cell lines (Heymach)
Combination Treatments for EGFR Acquired Resistance
JO25567 Study Design
Chemotherapy-naïve
Stage IIIB/IV NSCLC or
postoperative recurrence
Non-squamous
Activating EGFR mutations*
Exon 19 deletion
Exon 21 L858R
1:1
PS 0–1
Stratification factors: sex,
smoking status, clinical stage,
EGFR mutation type
*T790M excluded
Abstract 8005: Presented by Terufumi Kato
PD
E monotherapy
Erlotinib 150mg qd
(n = 75)
PD
R
Age ≥20 years
No brain metastasis
EB combination
Erlotinib 150mg qd +
bevacizumab 15mg/kg q3w
(n = 75)
•
•
•
Primary endpoint: PFS (RECIST v1.1,
independent review)
Secondary endpoints: OS, tumor response,
QoL, safety
Exploratory endpoint: biomarker assessment
Combination Treatments for EGFR Acquired Resistance
Primary endpoint: PFS by independent review
EB
E
Median (months)
1.0
HR
P value*
0.8
PFS probability
0.54 (95% CI: 0.36–0.79)
*log-rank test, two-sided
0.6
EB
E
0.4
0.2
9.7
0
16.0
0
2
4
6
8
10
12
Number at risk
EB
75
E
77
72
66
69
57
64
44
60
39
53
29
49
24
14 16 18
Time (months)
38
21
Abstract 8005: Presented by Terufumi Kato
30
18
20
12
20
22
24
26
28
13
10
8
5
4
2
4
1
0
0
Combination Treatments for EGFR Acquired Resistance
PFS by EGFR Mutation Type
Exon 19 deletion
Exon 21 L858R
EB group
E group
18.0
10.3
0.41
(95% CI: 0.24–0.72)
Median (months)
HR
1.0
Median (months)
HR
1.0
0.8
PFS probability
PFS probability
0.8
EB group
E group
13.9
7.1
0.67
(95% CI: 0.38–1.18)
0.6
0.4
EB
0.2
0.6
0.4
EB
0.2
E
E
0
0
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28
Time (months)
Time (months)
Number at risk
Number at risk
EB
40 39 38 36 33 29 27 24 19 12 8
5
2
2
0
EB 35 33 31 28 27 24 22 14 11 8
5
3
2
2
0
E
40 35 29 26 22 16 12 9
1
0
0
0
E
7
4
2
1
0
9
5
3
Abstract 8005: Presented by Terufumi Kato
37 31 28 18 17 13 12 12 9
7
Combination Treatments for EGFR Acquired Resistance
Toxicity with Tarceva + Avastin
JO25587
• No unforeseen toxicities or Rx-related deaths
• Grade >3 toxicity 91% vs. 53% (esp. HTN, proteinuria)
• 41% discontinued bevacizumab for adverse effects
– Primarily proteinuria (15%) or hemorrhagic (12%)
– Bevacizumab discontinuation rate 10-15% in BeTa,
ATLAS trials
Combination Treatments for EGFR Acquired Resistance
18
EGFR + NSCLC TrialsPFS (months)
16
16
13.1
14
13.6
11.0
12
10
Med
PFS (mo)
9.7
9.7
8
6
4
2
0
EURTAC 1
EURTAC
OPTIMAL 2
OPTIMAL
Lux-LUNG-3
LUXLung-33
Lux-Lung-6
LUXLung-64
JO-25567-E
JO25587Tarceva5
JO-25567-E/B
JO25587T/A5
1. Rosell et al. Lancet Oncol. 2012;13:239; 11. Zhou et al. Lancet Oncol. 2011;12:735; 3. Sequist et al. J Clin Oncol.
2013;31:3327; 4. Wu et al. Lancet Oncol. 2014;15:213; 5. Kato, Proc ASCO 2014, A#8005
Combination Treatments for EGFR Acquired Resistance
What’s next?
Akbay et al. Cancer Discovery 3:1355-1363, 2013
Combination Treatments for EGFR Acquired Resistance
Summary
• TWICE the opportunity for success, but
TWICE the side effects
• Upfront or after the development of
Acquired Resistance?
• Future Directions: Tarceva + PDL-1 inhibitor?